We are live on
!
Find out more
SAM
Strategy Asset Managers Portfolio holdings
AUM
$670M
1-Year Est. Return
34.04%
This Fund
S&P 500
This Quarter
Est. Return
+10.22%
1 Year Est. Return
+34.04%
3 Year Est. Return
+107.53%
5 Year Est. Return
+130.35%
10 Year Est. Return
+379.12%
AUM
$422M
AUM Growth
+$39.5M
(+10%)
Cap. Flow
+$5.79M
Cap. Flow
% of AUM
1.37%
Top 10 Holdings %
Top 10 Hldgs %
29.7%
Holding
240
New
12
Increased
81
Reduced
118
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$5.19M |
| 2 |
UnitedHealth
UNH
|
+$3.72M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.97M |
| 4 |
Dick's Sporting Goods
DKS
|
+$2.42M |
| 5 |
Air Products & Chemicals
APD
|
+$1.99M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$5.51M |
| 2 |
iShares US Medical Devices ETF
IHI
|
+$1.04M |
| 3 |
Medtronic
MDT
|
+$945K |
| 4 |
iShares Core US Aggregate Bond ETF
AGG
|
+$672K |
| 5 |
Corning
GLW
|
+$633K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.31% |
| 2 | Industrials | 12.36% |
| 3 | Healthcare | 11.57% |
| 4 | Financials | 10.86% |
| 5 | Communication Services | 5.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Indaptus Therapeutics
INDP
$144M
| $79.8K | 0.02% |
1,619
| – | – |
|
227
Dakota Gold
DC
$833M
| $64.2K | 0.02% |
24,500
-5,500
| -18% | -$14.8K |
|
|
NAK
228
Northern Dynasty Minerals
NAK
$913M
| $11.3K | ﹤0.01% |
35,000
| – | – |
|
|
229
iShares Core US Aggregate Bond ETF
AGG
$138B
| – | – |
-7,148
| Closed | -$672K |
|
230
Brown-Forman Class B
BF.B
$13B
| – | – |
-3,818
| Closed | -$220K |
|
231
Clorox
CLX
$12.8B
| – | – |
-1,841
| Closed | -$241K |
|
232
Emcor
EME
$37B
| – | – |
-953
| Closed | -$201K |
|
233
First Trust NYSE Arca Biotechnology Index Fund
FBT
$2.77B
| – | – |
-3,152
| Closed | -$461K |
|
|
234
iShares US Medical Devices ETF
IHI
$3.46B
| – | – |
-21,355
| Closed | -$1.04M |
|
235
KBR
KBR
$4.83B
| – | – |
-4,133
| Closed | -$244K |
|
236
McCormick & Company Non-Voting
MKC
$14.7B
| – | – |
-2,962
| Closed | -$224K |
|
237
RTX Corp
RTX
$300B
| – | – |
-4,280
| Closed | -$308K |
|
238
J.M. Smucker
SJM
$13B
| – | – |
-2,161
| Closed | -$266K |
|
239
iShares TIPS Bond ETF
TIP
$14.7B
| – | – |
-3,486
| Closed | -$362K |
|
240
T. Rowe Price
TROW
$23.5B
| – | – |
-2,050
| Closed | -$215K |
|
Similar funds
TAP
CCM
BCP
AVM
FAM
MCO
CCG
PAI
Strategy Asset Managers's Q4 2023 Portfolio in Review
As of Q4 2023, Strategy Asset Managers held 240 positions worth $422M, up 10% from $382M the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Strategy Asset Managers's Q4 2023 filing shows 12 new, 81 increased, 118 reduced and 12 closed positions. Its largest new stake was Dick's Sporting Goods: 19,908 shares worth $2.93M. The largest sale was Pfizer, an estimated $5.51M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 21% a quarter earlier, followed by Industrials and Healthcare.
- Strategy Asset Managers's largest Q4 2023 buy was Dick's Sporting Goods: 19,908 shares worth $2.93M.
- Strategy Asset Managers added most to Eli Lilly in Q4 2023, an estimated $5.19M increase.
- Strategy Asset Managers's biggest Q4 2023 reduction was Pfizer, cutting an estimated $5.51M.
- Strategy Asset Managers fully exited iShares US Medical Devices ETF in Q4 2023, selling an estimated $1.04M.
- Strategy Asset Managers's ten largest holdings make up 30% of its $422M portfolio in Q4 2023.
- Strategy Asset Managers opened 12 new positions and closed 12 in Q4 2023.
- Strategy Asset Managers's portfolio value rose 10% quarter-over-quarter to $422M.
Based on Strategy Asset Managers's 13F filing for Q4 2023, filed 12 Feb 2024.